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Abstract: The reconstruction of large bone defects requires the use of biocompatible osteoconductive
scaffolds. These scaffolds are often loaded with the patient’s own bone marrow (BM) cells to facilitate
osteoinductivity and biological potency. Scaffolds that are naturally sourced and fabricated through
biomorphic transitions of rattan wood (B-HA scaffolds) offer a unique advantage of higher mechanical
strength and bioactivity. In this study, we investigated the ability of a biomorphic B-HA scaffold
(B-HA) to support the attachment, survival and gene expression profile of human uncultured BM-
derived mesenchymal stromal cells (BMSCs, n = 6) and culture expanded MSCs (cMSCs, n = 7) in
comparison to a sintered, porous HA scaffold (S-HA). B-HA scaffolds supported BMSC attachment
(average 98%) and their survival up to 4 weeks in culture. Flow cytometry confirmed the phenotype
of cMSCs on the scaffolds. Gene expression indicated clear segregation between cMSCs and BMSCs
with MSC osteogenesis- and adipogenesis-related genes including RUNX2, PPARγ, ALP and FABP4
being higher expressed in BMSCs. These data indicated a unique transcriptional signature of BMSCs
that was distinct from that of cMSCs regardless of the type of scaffold or time in culture. There was no
statistical difference in the expression of osteogenic genes in BMSCs or cMSCs in B-HA compared to
S-HA. VEGF release from cMSCs co-cultured with human endothelial cells (n = 4) on B-HA scaffolds
suggested significantly higher supernatant concentration with endothelial cells on day 14. This
indicated a potential mechanism for providing vasculature to the repair area when such scaffolds are
used for treating large bone defects.
Keywords: mesenchymal stromal cells (MSCs); biomorphic scaffolds; bone regeneration; gene expression
1. Introduction
Bone healing and repair following trauma remains a challenging physiological pro-
cess, especially for patients who suffer from severe fracture injuries or have associated
comorbidities such as obesity or diabetes. The risk of an impaired healing response is
also higher in patients with osteoarthritis, who may need surgical treatments alongside
drug intervention for enhanced osseointegration of the implants [1,2]. This impaired bone
healing process often leads to a greater risk of fracture non-union, a complication that could
require multiple surgical interventions with increased medical and societal costs [3].
Lately, the use of biomaterial scaffolds using the so-called ‘diamond concept’ has
significantly improved the bone healing response and outcomes in such difficult clinical
situations [4]. In brief, the concept involves the use of a platform/biomaterial that serves as
the scaffold (matrix) onto which bone forming cells are added or can migrate to, under the
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influence of growth factors (inductive molecules) to encourage bone regeneration. Finally,
the mechanical strength of the metalwork, as well as the scaffold itself, plays a crucial role
in providing the necessary stability to the repair area.
Bone by itself is an extremely dynamic organ with unique microarchitecture to support
the formation and activities of a plethora of cells inside its niche. Within the bone, the bone
marrow (BM) compartment is the seat of these activities that determine the ability of the
bone to repair, regenerate and become healthy once again. The progenitors of bone residing
within the BM are mesenchymal stromal cells (MSCs) that drive the process of osteogenesis
with the help of various growth factors [5]. MSCs provide niche support to haematopoietic
and endothelial cells; differentiate into at least bone, fat and cartilage and are increasingly
being used for the investigation of bone regeneration processes in vitro, including those on
different types of biomaterial scaffolds [6].
Interestingly, the majority of the studies performing these investigations are utilising
culture-expanded MSCs (cMSCs) [7–9]. Nonetheless, using cMSCs does not necessarily
mirror the bone healing mechanisms in vivo as they themselves undergo replicative senes-
cence during culturing over time [10]. On the other hand, MSCs from fresh BM aspirates
withdrawn from patients (BMSCs) are increasingly used in the orthopaedics practice as
a one-stage surgical procedure, either alone or following loading on a relevant bone scaf-
fold [11]. Although there exist a plethora of studies investigating the behaviour of cMSCs
on biomaterial scaffolds, similar studies with BMSCs remain scarce but provide a better
insight towards repair mechanisms that occur following scaffold implantation.
Large 3D porous hydroxyapatite scaffolds with biorelevant ionic substitutions (B-HA
scaffolds) have been recently produced through the biomorphic transformation of a natural
wood (rattan wood pieces or Calamus manna) [12,13]. Compared to sintered, HA-based
ceramics with isotropic porosity, B-HA scaffolds contain hierarchically organised, wide,
aligned channels of ~300 µm and smaller connected tubules mimicking the microstructure
and the mechanical stiffness of the cortical bone shell, thus, making them ideally suited
for weight-bearing, long-bone fracture repair. The scaffolds are prepared using various
manufacturing steps to encourage the dissolution of calcite and re-precipitation of HA-
nanocrystals of ~20 nm in thickness and ~150 nm in width and are additionally reinforced
with Mg2+ and Sr2+ ions for enhanced biocompatibility, osteogenesis as well as better
mechanical properties [14]. Previous biocompatibility studies using B-HA scaffolds have
been performed using cultured BM MSCs from mice (C57BL/6) [12] or human adipose
tissue–derived stem cells [14]. No study as yet has investigated their support for human
BM MSCs, particularly those from unprocessed BM aspirates (BMAs).
The principal aim of this study was, therefore, to evaluate the support functions of
B-HA scaffolds towards rare, uncultured BMSCs from human BMAs and compare BMSCs
with cMSCs. Our secondary aim was to compare B-HA scaffolds with a sintered HA scaffold
(S-HA) with a classical macro-, micro- and interconnected porosity. As a result, we provide
evidence for MSC attachment, survival and gene expression of transcripts associated with
multiple MSC functions including bone formation and angiogenesis support on B-HA
and demonstrate their release of VEGF protein essential for vascular formation around
the construct.
2. Materials and Methods
2.1. Ethics and Sample Processing
Ethical approval was obtained from the NREC Yorkshire and Humberside National
Research Ethics Committee (numbers 18/YH/0166 and 06/Q1206/127) for the collection
of samples from human donors.
For seeding the scaffolds with cMSCs, frozen vials of previously culture-expanded
and characterised passage 2 MSCs (n = 7 donors, age range 19–65 years old) were defrosted
in complete DMEM media containing 10% FBS and 1% P/S (Thermo Scientific, Loughbor-
ough, UK) and cultured in StemMACS (Miltenyi Biotec, Bisley, UK) (SM) to obtain up to
2 × 106 MSCs.
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For seeding the scaffolds with fresh BM aspirates (BMAs), BMA was collected from
patients undergoing metal removal or fracture reconstruction (n = 6 donors, age range
36–65 years old). Three additional donors (age range 41–52) were recruited for VEGF ELISA
measurements. The patients were deemed to be otherwise healthy. An average of 4 mL of
BMA was collected in tubes containing ethylenediamine tetraacetic acid (EDTA) to prevent
clotting. The collected tubes were then taken to the laboratory for further processing.
A simple schematic summary of all the experiments performed is shown below
in Figure 1.
Figure 1. Schematic summary of all the experiments performed.
2.2. Scaffolds, Cell Loading and Culturing on Scaffolds
B-HA manufacture and physical and mechanical properties have been described
previously [12]. In brief, cylindrical rattan wood pieces (Calamus manna) were trans-
formed to CaCO3 using a series of physicochemical treatments and gas under supercritical
conditions [12]. Then, the obtained CaCO3 body was finally transformed through hy-
drothermal reactions into a biomorphic apatite body presenting multiple doping with Mg2+
and Sr2+. The resulting scaffolds were 10 mm in diameter with a specific surface area of
12.30 m2 g−1 [12]. Commercially available, porous HA scaffolds (S-HA) with an almost
90% porosity and broadly similar size and surface area (diameter 9 mm, surface area of
64 mm2) and main pore size of 100–200 µm were used as controls. Microscopic images
(AMG EVOS fl-fluorescence microscope) of both scaffolds at 4X using transmitted light
have been provided in Supplementary Figure S1 to highlight the scaffold structures. Before
adding cMSCs or BMSCs for in vitro biological evaluations, the scaffolds were primed in
SM at 37 ◦C and 5% CO2 for 72 h. This was performed to enable the ionic equilibrium in
the media [12] around the scaffolds, as well as to provide MSC attachment factors in the
SM media [15]. For loading scaffolds with BMA, primed B-HA scaffolds were placed in a
24-well plate and loaded with 316 µL of BMA (in duplicate) for 3 h at 37 ◦C. To account for
small differences in scaffold volumes, duplicate S-HA scaffolds were loaded with 256 µL
of BMA.
To measure rare BMSC attachment to the scaffolds, CFU-F assay was used as previously
described [15]. For this, 200 µL BMA was seeded in duplicate 100 mm Petri dishes (Corning,
New York, NY, USA) containing 10 mL SM media as ‘before attachment’ controls and
cultured for 2 weeks as per the standard colony forming unit fibroblast (CFU-F) assay
protocol [16,17]. After the 3 h incubation period of BMA with the scaffolds, the latter was
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moved to low-attachment 24-well plates and covered with 1.5 mL SM media. After 24 h,
a complete media change was performed, and the aspirated media (containing any non-
attached MSCs) were plated in another set of duplicate CFU-F dishes to ultimately calculate
the proportions of non-attached MSCs. The attached MSCs were subsequently calculated
by subtraction [15]. To study long-term MSC survival in standard, static conditions, the
scaffolds were cultured in low-attachment 24-well plates (Scientific Laboratory Supplies,
Nottingham, UK) in SM media for 1, 2 and 4 weeks with half-media changes performed
twice a week.
For seeding the scaffolds with cMSCs, the frozen vials of passage 2 cells were defrosted
and revived in SM media overnight before seeding them on the scaffolds. On the day of
seeding, 2 × 105 MSCs per scaffold were re-suspended in 316 µL of SM media and added
to primed B-HA scaffolds in duplicate for 3 h. Similarly, 1.6 × 105 cells in 256 µL were
added to S-HA scaffolds owing to their smaller surface area. After the incubation, the
scaffolds were moved to a low-attachment 24-well plate and cultured for 1, 2 and 4 weeks.
Similarly to the cultures established with BMSCs, each well with a cMSC-seeded scaffold
was fed with 1.5 mL of SM media and a half-media change was performed twice weekly.
The attachment of cMSCs was calculated by counting any non-attached cells after 24 h and
relating it to the numbers of seeded cMSCs.
2.3. Cell Extraction from Scaffolds to Test for MSC Survival
The extraction of cells from the scaffolds was performed from one of the duplicate
scaffolds following the collagenase/trypsin treatment protocol, as previously described [15].
At the end of each time point, scaffolds were washed three times with 2 mL PBS and first
treated with 0.5 mL trypsin (both from Life Technologies, Paisley, UK) for 10 min in 37 ◦C.
The activity of trypsin was blocked by the addition of 10 µL of volume for 10% FCS for
5 min. Next, 0.5 mL of collagenase (Stem Cell Technologies, Vancouver, BC, Canada) was
added to the scaffolds and incubated at 37 ◦C for 0.5 h with regular manual agitation to
ensure the removal of all cells. The collagenase fraction was then added to the trypsin
fraction and passed through a 70 µm cell strainer (Thermo Fisher Scientific) to remove any
debris from the scaffolds. The released cells were counted using trypan blue and used for
subsequent flow cytometry (for cMSCs, see below section) or CFU-F assay (for BMSCs)
for evaluation of MSC maintenance. For CFU-F assay with cells released for the scaffolds
loaded with BMAs, the released cells were seeded into six-well plates (Corning). Any
colonies derived from released cells were counted after staining with methylene blue and
compared to seeded MSCs.
2.4. Flow Cytometry
To prove the MSC identity of the cells released from the scaffolds seeded with cMSCs,
flow cytometry was performed as previously described [18]. Released cells were distributed
in two FACS tubes and stained with CD45 Viogreen and CD90-FITC (tube 1) or CD105 FITC
and CD73 PE (tube 2) (all reagents from Miltenyi Biotec) for 15 minutes in the dark before
washing and centrifuging to obtain a pellet. The pellets were then re-suspended in 500 µL
FACS buffer containing 7-AAD (Miltenyi Biotec) and analysed using a flow cytometer,
Attune (Thermo Fisher Scientific, Waltham, MA, USA). All the events were displayed on
forward (FSC) and side scatter (SSC) images. Following this, doublets and any other events
were eliminated to gate cells only using the height and area of FSC (FSC-A and FSC-H).
After that, 7-AAD was used to identify the live cells from which MSCs were evaluated
using the expression of CD105, CD73 and CD90 and the lack of CD45.
2.5. Gene Expression
The second scaffolds’ duplicate was treated with 350 µL of Buffer RL (Norgen Biotek,
Thorold, ON, Canada) to lyse the cells inside the scaffolds with strong agitation using
vortex over ice to ensure removal of all the cells with their genetic contents and prevent
RNA degradation. Gene expression was performed on a predetermined panel of genes
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associated with MSC functionalities (Supplementary Table S1) as per methods described
previously [19,20]. Briefly, RNA was extracted from the cells from the scaffolds collected in
the buffer RL and reverse transcribed to complementary DNA (cDNA). The cDNA was pre-
amplified using 14 cycles and PA master mix using Fluidigm (Fluidigm, San Fransisco, CA,
USA) reagents as per the manufacturer’s protocols for scaffolds established from cultured
MSCs or BMAs, respectively. Quantitative polymerise chain reaction (qPCR) was then
performed on a Fluidigm 48.48 Dynamic ArrayTM integrated fluid circuit (IFC, Fluidigm)
using HPRT1 and as the housekeeping gene. The Ct values of the genes of interest were
normalised to the housekeeping gene and then calculated for their relative expression as
2−∆Ct using the formula ∆Ct = Cttarget gene − Cthousekeeping gene. Cluster (version 3.0) and
Java TreeView (version 1.1.6r4) software were used to generate clusters of gene expression of
log2 transformed data for visualisation via heatmaps. The expression of genes is indicated
in red (+3, highest) or green (−3, lowest) compared to HPRT1. Grey squares indicate values
that were below detection levels, and black squares indicate values close to 1.
2.6. Enzyme Linked Immunosorbent Assay (ELISA)
ELISA was performed to measure VEGF in supernatants collected from B-HA/cMSCs’
constructs (n = 4) seeded either alone or co-cultured along with human umbilical vein en-
dothelial cells (Promocell, Heidelberg, Germany) for 2 weeks. HUVECs were grown to con-
fluence in T75 flasks using endothelial media (Promocell) and seeded at 1 × 105 HUVECs
per scaffold in duplicate, together with 1 × 105 cMSCs per scaffold in media containing
endothelial media: SM media in the ratio 1:1 to ensure growth of both the cMSCs as well
as the HUVECs. Scaffolds seeded with MSC only (2 × 105 cMSCs per scaffold) served as
controls, and the supernatants were collected on days 1, 7 and 14 and frozen at −80 ◦C. A
full-media change was performed on day 1 followed by half-media changes twice/week.
The ELISA was performed as per the manufacturer’s protocol. In brief, supernatant samples
were defrosted, and the VEGF standard dilutions were prepared and added to the 96-well
plate. Next, 50 µL of sample diluent followed by 50 µL of supernatant sample was added to
the remaining wells in a pre-determined sequence. The plate was incubated for 2 h at room
temperature (RT) followed by the addition of biotin conjugate, streptavidin–horseradish
peroxidase (HRP), 3,3′,5,5′-tetramethylbenzidine (TMB) solution and stop solution with
washing and incubation in between each step. Finally, the colour change of the plate (VEGF
ELISA Kit, Invitrogen) was read at 450 nm using the Cytation 5 imaging plate reader (Bio
Tek), and GraphPad Prism software (version 9.2) was used to produce a standard curve
and generate values of VEGF for all samples.
2.7. Statistics
Statistical analysis and graphical representations of the data were performed using
GraphPad Prism (version 9.2.0). Normal distribution of the data was checked using the
Shapiro–Wilk and Kolmogorov–Smirnov tests. For data that were not found to be normally
distributed, the Mann–Whitney test was used for unpaired data and the Wilcoxon signed
rank test for paired data. Statistical analysis of data across three time points (week 1,
week 2 and week 4) was carried out using one-way ANOVA followed by Kruskal–Wallis
non-parametric test with Dunn correction for multiple groups. The results were considered
significant at a p value of <0.05.
3. Results
3.1. cMSCs and BMSC Attachment and Survival on B-HA Scaffolds
The aim of these experiments was to investigate and compare the attachment of
cMSCs and BMSCs to B-HA scaffolds and to evaluate their survival in comparison to
S-HA scaffolds during long-term culture in static conditions. To study BMSC survival,
BMA-loaded scaffolds were maintained in culture for 4 weeks. Cells were extracted from
the scaffolds at week 1, 2 and 4, and BMSCs were quantified using a CFU-F assay (Figure 2).
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Figure 2. BMSC and cMSC attachment and survival on the scaffolds. (A) Examples of BMSC colonies
(CFU-F) following the plating of BMA without any scaffolds (left), BMSC colonies/CFU-F non-
attached on B-HA (centre) and S-HA (right) after 24 h of adding BMA to the scaffolds. (B) BMSC
attachment to scaffolds measured as the percentage of attached CFU-Fs to both scaffolds relative to
seeded CFU-F; (C) BMSC maintenance measured as the percentage of BMSCs extracted after week 1,
2 and 4 of culture; (D) cMSC maintenance measured as the percentage of cMSCs extracted after week
1, 2 and 4 of culture using trypan blue for cell counts. Data are shown with mean and standard error
of mean and with n = 3 cMSCs and n = 6 BMSCs.
To analyse the attachment of fresh BMSCs to the scaffolds, unprocessed BMA was
added to the scaffolds for 3 h, after which the scaffolds were transferred to a low-attachment
24-well plate and maintained in culture. The same unprocessed BMA was plated on
100 mm Petri dishes in the CFU-F assay as ‘before attachment’ control (Figure 2A(left)).
After 24 h, full-media change was performed, and all BMA cells non-attached to the
scaffolds were plated in 100 mm Petri dishes to establish the proportion of unattached
BMSCs (Figure 2A(right)), from which the proportion of attached BMSCs was calculated by
subtraction. The analysis revealed that B-HA scaffolds provided better BMSC attachment
than S-HA; however, the differences were not statistically significant (Figure 2B(left)).
The relatively lower percentage of cells extracted from the B-HA scaffolds could be
attributed to their unique longitudinal porosity, which is a characteristic of the scaffold,
making it difficult to extract cells that were trapped within these distinctive pores. This is
observed especially at week 1, when the resorption rate is the lowest (Figure 2C,D). It is
speculated that, with the passage of time in weeks, the rate of resorption increased, and it
was easier to extract the cells from the nanostructural pores indicated.
Finally, scaffolds’ support to uncultured BMSCs was compared to their support for
cMSCs. Following seeding, BMSCs and cMSCs were extracted at week 1, 2 and 4, and
results indicated no significant differences between the scaffolds and a higher BMSC
and cMSC survival at week 2 (Figure 2C,D). Altogether, these data indicated that both
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scaffolds supported the attachment and survival of cMSCs at least up to week 2 in standard,
static conditions.
To confirm the MSC identity of the cells extracted from the scaffolds, they were
analysed using flow cytometry using a panel of standard MSC markers [21] (gating strategy
described in Figure 3A–C). The data were analysed as a percentage of marker-positive
cells relative to total live cells (Figure 3). A higher percentage of CD73-, CD105- and CD90-
marker-positive cells were observed from the cells extracted from S-HA. These differences
were statistically significant as compared to those extracted from B-HA scaffolds for CD105
at week 1 (p = 0.0404), week 2 (p = 0.0221) and week 4 (p = 0.0406) and also for CD73
at week 1 (p = 0.0329), week 2 (p = 0.0283) and week 4 (p = 0.0388). The decline in MSC
markers in cells seeded on B-HA scaffolds indicated their potential differentiation, which
was studied next using gene expression evaluation.
Figure 3. Phenotypic analysis of cMSCs after extraction from B-HA and S-HA scaffolds. (A–C) Gating
strategy from all events (A) to gating on live 7-AAD-negative cells (B) and calculation the percentage
of marker-positive cells based on histogram (C). (D–F) Percentage expression of MSC markers on the
extracted cells from both scaffolds at week 1, week 2 and week 4 for CD90 (D), CD73 (E) and CD105
(F). Results are shown as mean with standard error of mean for n = 3 cMSCs. * p < 0.05.
3.2. Gene Expression of cMSCs and BMSCs Extracted from Scaffolds
Gene expression analysis of 48 transcripts (Supplementary Table S1) was performed
on cMSCs and BMSCs lysed from both scaffolds at week 1, 2 and 4 of culture.
The cluster analysis revealed clear segregation of BMSCs, outlined in a blue box on
the right, and cMSCs, outlined in a yellow box on the left, irrespective of the time in culture
and the scaffolds used (Figure 4). For BMSCs, a further two clusters could be observed,
outlined by black and brown boxes, the former being enriched for B-HA samples and the
latter being enriched for S-HA samples. This segregation was not as obvious in cMSC
samples, suggesting greater differences between the scaffolds when they are loaded with
uncultured BMSCs.
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Figure 4. Cluster analysis of all samples and all genes. Cluster analysis of cMSCs and BMSCs after
lysis from B-HA and S-HA scaffolds. Labels on the right indicate the genes, and labels on the top
indicate samples. The range of gene expression levels varies from the highest expression in red to the
lowest in green. Their colour key for the relative expression is on the right. Data are presented for
n = 3 cMSCs and n = 6 BMSCs, coloured boxes are explained in the text.
In terms of gene clustering, three major groups of genes were evident: those with an
overall higher expression in BMSCs (top cluster, genes outlined in purple), those with an
overall higher expression in cMSCs (bottom cluster, genes outlined in green) and those
with similar expression (middle cluster, genes in between the purple and green clusters).
For example, osteogenesis- and bone-formation-related E11, COL10A1, ALP, RANKL,
OPN and adipogenesis-related PPARγ and FABP4 were highly expressed in BMSCs as
compared to cMSCs (outlined in purple). This potentially suggests that BMSCs on B-HA
maintained higher osteogenic and adipogenic abilities compared to cMSCs. Interestingly,
the chondrogenic transcripts ACAN, COMP and SOX9 were overall higher expressed in
cMSCs than in BMSCs (outlined in green), potentially suggesting a better chondrogenic
ability for cMSCs than for BMSCs when cultured on these scaffolds.
3.3. Gene Expression Changes in cMSCs Present in Both Scaffolds
As the cluster analysis revealed clear segregation between cMSCS and BMSCs (Figure 4),
a more detailed analysis of their gene expression was next performed on these cells sep-
arately (Figures 5 and 6). It was found that 38 out of 48 transcripts (79%) were highly
and consistently expressed in cMSCs present in B-HA and S-HA scaffolds, and these are
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shown in Figure 4. As seen from this figure, all cMSCs expressed high levels of transcripts
encoding many proteins and enzymes involved in extracellular matrix (ECM) turnover
(including different MMPs and TIMPs) as well as several bone- and cartilage-specific
structural proteins such as SPARC and ACAN. The cells also expressed classical MSC
transcripts NT5A and THY1; trophic factors VEGFA, VEGFC and CXCL12 and all three
MSC lineage transcription factors (TFs): Sox9 (cartilage), PPARγ (fat) and RUNX2 (bone).
This gene expression pattern was consistent with cMSCs, which are characterised by a
notable absence of mature, fat-lineage proteins [22]. There were no notable differences
between cMSCs present in B-HA and S-HA other than a less uniform expression of E11
(a marker of early osteocytes) and BGLAP in S-HA (Figure 5). In addition, there were no
statistically significant increases or decreases in gene expression levels with time in culture,
although a number of the transcripts displayed a trend for increased levels from week 1 to
week 4, potentially indicating higher transcriptional activity in the cells at week 4.
Figure 5. Gene expression of cMSCs normalised to HPRT. Top panel shows the gene expression of
transcripts on B-HA, and the bottom panel shows gene expression of transcripts on S-HA for week 1,
2 and 4. Data were normalised to the housekeeping gene HPRT1, indicated with the black horizontal
line. Black arrows indicate genes that displayed expression levels lower than that of the housekeeping
gene. Data are shown as mean with standard error of mean for n = 3 cMSCs.
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Figure 6. Gene expression of BMSCs normalised to HPRT. Top panel shows the gene expression of
transcripts on B-HA, and the bottom panel shows gene expression of transcripts on S-HA for week 1,
2 and 4. Data were normalised to the housekeeping gene HPRT1, indicated with the black horizontal
line. Black arrows indicate genes that displayed expression levels lower than that of the housekeeping
gene. Data are shown as mean with standard error of mean for n = 6 BMSCs.
3.4. Gene Expression of BMSCs Present in Both Scaffolds
In all, 34 out of 48 transcripts (71%) were highly and consistently expressed in BMSCs
present in B-HA and S-HA scaffolds (Figure 6). Similar to scaffolds seeded with cMSCs,
BMSCs expressed high levels of transcripts encoding ECM proteins and enzymes as well as
several bone-specific structural proteins such as SPARC and SPP1. In addition to classical
MSC transcripts NT5A and THY1, a relatively high expression of PTPRC indicated the
attachment and persistence of haematopoietic-lineage cells from BMA, some of which (such
as macrophages) could be useful for bone regeneration [23,24]. BMSCs also expressed
relatively high levels of VEGFA, VEGFC and CXCL12 as well as bone- and fat-lineage TFs
RUNX2 and PPARγ. Compared to cMSCs, the cells displayed prominent expression of
fat-lineage mature protein FABP4 and lacked Sox9 TF expression, indicating a tilt towards
adipogenesis, characteristic for BMSCs compared to cMSCs [22,25]. There were some
differences between B-HA and S-HA scaffolds, such as notable expression of ACAN
and MMP9 in BMSCs present in B-HA and higher/more consistent expression of p16
(senescence marker) and RANKL (bone resorption driver) in BMSCs present in S-HA
(Figure 6). Similar to cMSCs, there were no statistically significant increases or decreases
in gene expression levels with time in culture, although the majority of the transcripts
displayed a trend for increased levels from week 1 to week 4, potentially indicating higher
transcriptional activity in the cells at week 4.
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3.5. VEGF Production by cMSCs Alone or in Co-Culture with Endothelial Cells on B-HA Scaffolds
VEGF production by MSCs is critically important for bone regeneration [26,27]. As we
detected VEGF expression in cMSCs at the transcript level, it was important to evaluate
VEGF protein release by MSCs cultured on B-HA, which we next measured at days 1, 7
and 14 of culture using ELISA (Figure 7A). Over the 14 days, a half-media change was
performed to maintain the culture. This would impact the level of VEGF produced. For
example, on day 1, the level would be high, and after the following media change, the
concentration of VEGF would be reduced. Thus, to account for the media change affecting
the VEGF concentrations, data were also presented as cumulative VEGF levels (Figure 7B).
Figure 7. VEGF production by cMSCs cultured on B-HA. (A) VEGF concentrations in supernatants
collected from cMSCs in comparison with cMSCs co-cultured with endothelial cells (+E) in B-HA and
(B) cumulative VEGF release with time in culture. Results are shown as mean with standard error of
mean for n = 4 cMSCs. * p < 0.05.
The concentration of VEGF in all samples on day 1 was between 50 and 150 pg/mL
(Figure 7A). On day 1, the VEGF level was higher in supernatants from cMSCs than in
cMSCs + E, as expected [28]. From day 7 onwards, the supernatant levels of VEGF declined
in cMSCs but not in cMSCs + E cultures. As the cultures were fed with fresh media several
times during these two-week-long experiments, VEGF cumulative release was calculated,
taking media dilutions into account, and revealed an increase in VEGF production, particu-
larly in cMSCs + E cultures (p = 0.0129), potentially indicating a paracrine mechanism of its
production. These data confirmed the viability and functional angiogenesis-supporting
potency of cMSCs present in B-HA scaffolds.
For comparison with cMSCs, we also investigated the VEGF levels from BMSCs from
n = 3 donors in standard 2D (without scaffolds) conditions. We found the VEGF release
to be between 99 and 148.7 pg/mL on day 14 from an average of 104 seeded BMSCs
(Supplementary Table S2).
4. Discussion
Fracture non-union and bone defects, particularly in weight-bearing long bones,
continue to represent a significant clinical challenge. Firstly, the natural architecture of
a long bone, as well as the need to withstand considerable and directional mechanical
loads, dictates the development of scaffolds with very high mechanical strength, anisotropy,
complex geometry and multiscale porosity [29,30]. Secondly, bone reconstruction with
these synthetic scaffolds requires biological stimulation, either in a form of growth factors
or osteogenic stem cells such as autologous cMSCs or BMSCs. The latter are preferentially
used by the orthopaedic surgeons as they are not regulated as advanced therapy medicinal
products (ATMPs) [31]. Finally, blood supply to the entire repair area remains a considerable
challenge and requires novel approaches in scaffold fabrication, specifically for angiogenesis
stimulation [13,29]. Biomimicking is a new development in bone scaffold fabrication,
which capitalises on the evolutionally developed, highly hierarchical structures that serve
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as sacrificial templates for chemical transformation and reinforcement [32]. Wood in
particular has a highly anisotropic structure characterised by long parallel channels (used
in plants to transport water and nutrients) that have variable lumen diameters and inherent
interconnectivity [32] that closely mimic the Haversian and Volkmann canals in human
cortical bone [33]. Rattan wood has another advantage of having evenly distributed
directional channels (with no seasonal rings) [34], which are particularly suitable to act
as conduits for blood vessel ingrowth, as well as the lacunar fractal nature of porosity,
influencing its material strength and stiffness [34].
Previous studies have investigated the biomechanical properties and biocompatibility
of rattan-templated biomorphic scaffolds (B-HAs) using primary mouse and human cells,
including adipose-derived stem cells (ASCs) [12–14,30,34]. The current study is the first to
investigate the attachment, survival and gene expression of MSCs harvested from human
bone marrow, the MSC source easily accessible to an orthopaedic surgeon and commonly
used for bone reconstruction, with a particular emphasis on uncultured BMSCs that do
not require ATMP regulation. BM as an easily accessible source of BMSCs was used in
this study to closely reflect in vivo conditions. Towards the third challenge in large-scale
defect reconstruction, this study investigated the long-term release of VEGF following
B-HA scaffold colonisation by cMSCs.
Previously, Sprio et al. have demonstrated the biocompatibility of B-HA scaffolds
using mouse (C57BL/6) MSCs and human adipose-derived stem cells (hADSCs). In their
first study, they demonstrated the use of Sr2+-substituted scaffolds for enhanced bone
formation abilities, bioactivity and biocompatibility in a rabbit animal model [35]. In
another study, they further confirmed their enhanced bioactivity and compressive strength
using human-derived ADSCs [13]. In contrast, the current study focused on patient-derived
uncultured BMSCs, as these cells most closely reflect the bone marrow in vivo. Furthermore,
their initial work used dynamic seeding, and their most recent work explored the gene
expression of osteogenic transcripts in osteogenic media [36]. In contrast, the principal
aim of this work was to investigate the feasibility of loading the B-HA scaffolds with
unprocessed BM aspirates, as happens in the operating theatre, and to study the attachment,
survival and gene expression of BMSCs on B-HA in comparison to that of cMSCs. We also
used standard, sintered, isomorphic, highly porous S-HA scaffolds as control and standard
SM media that are established for growing fresh BMSCs from unprocessed BM aspirate.
We tested cMSCs and BMSCs from a broad age range of donors (19–65 years old) and
provided a gene expression dataset for a large number of genes reflecting MSC differentia-
tion and trophic capacities and angiogenesis-related genes. We observed a clear distinction
between the levels of expression of genes between BMSCs and cMSCs but not so much be-
tween B-HA and S-HA. This indicated that, in terms of MSC gene expression maintenance,
B-HA was not inferior to S-HA. The differences between BMSCs and cMSCs present within
B-HA (or S-HA) resembled those found between uncultured and 2D-cultured MSCs, as
previously shown by us and others [22,25]. These differences primarily relate to the better
maintenance of adipogenic differentiation capacity in uncultured MSCs. Overall, our gene
expression findings revealed good maintenance of undifferentiated MSC transcriptional
signature with prominent osteogenic and adipogenic gene expression profiles up to 4 weeks
in standard, static MSC culture conditions.
Secondly, we successfully showed that B-HA supported the attachment of BMSCs to
the same level as S-HA (nearly all colony-forming MSCs were attached). The survival of
MSCs in both scaffolds followed a similar pattern of an initial decline at week 1 followed
by a ‘recovery stage’ at week 2 and, again, a decline at week 4. These patterns were not
specific to B-HA, which argues against a specific inhibitory environment provided by B-HA,
and there remains a possibility that some cells remained attached to scaffolds after our
collagenase/trypsin-based extraction treatment. This could also be attributed to the unique
porosity of B-HA scaffolds that might have prevented the removal of all cells from the
pores in the first week. Future work should utilise in situ confocal staining for cell nuclei or
cell metabolic activity or DNA assays to better quantify the maintenance of MSCs on these
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scaffolds. We also noted that BMSC maintenance on both scaffolds was lower than cMSC
maintenance, possibly due to the extreme rarity of MSCs in BMA and, subsequently, their
lower seeding density per scaffold (on average 16 and 13 BMSCs cells per B-HA and S-HA,
respectively, compared to an average of 2 × 105 and 1.6 × 105 cMSCs, respectively). Future
studies should investigate whether the pre-treatment of B-HA with a biocompatible ECM,
such as collagen [15,37], could improve MSC maintenance inside the scaffold.
As mentioned, B-HA possess a unique structure suitable for blood vessel ingrowth into
the construct. For the development of vascularised long-bone grafts, nature-inspired as well
bioprinted scaffolds have been tested in the past. B-HA has been previously shown to have
enhanced mechanical strength and bone regeneration abilities [13]. Using a 3D printing,
Sprio et al. have demonstrated good colonisation of Haversian-canal-mimicking pores
with both MSCs and HUVECs, as well as the clear benefits of MSC/HUVEC co-culture
for both osteogenesis and angiogenesis, compared to MSC- or HUVEC-alone groups [29].
In our study, we confirmed the benefits of co-culturing cMSCs and HUVECs, at least in
terms of VEGF production. In contrast to Sprio et al.’s 2020 study [13], we did not use a
sequential seeding strategy or grown cells in the osteogenic media. The optimal way of
establishing vascularised bone models, in terms of cell seeding, culture conditions and
media used, remains to be established and validated between the different groups [38]. To
capitalise on the unique water transport ability of the wood templates, cell seeding could be
performed using a ‘bottom-up’ approach, as recently demonstrated in Liu et al.’s study [39].
Nevertheless, despite some differences in the methodologies and MSC types used, our
results are consistent with those shown by Simone et al. [13], in that the B-HA scaffolds
provide a beneficial environment for angiogenesis, co-existence of MSCs and endothelial
cells and the production of VEGF.
5. Conclusions, Limitations and Future Perspectives
For the first time, we have performed a study comparing cMSCs and BMSCs on B-HA
scaffolds using a wide panel of genes. We provide evidence for B-HA supporting the
attachment and survival of cMSCs and BMSCs for up to 4 weeks as indicated by gene
expression data. We also found higher levels of VEGF in cMSCs co-cultured with HUVECs
on day 14. The data were found to be encouraging towards future studies involving a
larger donor cohort of human samples.
This study is limited by the number of donors (n = 7 for cMSCs and n = 6 for BMSCs)
for experiments with scaffolds; however, similar studies with B-HA or S-HA had utilised
even fewer cultures or single immortalised cell lines [12]. We acknowledge the variation
and the low abundance of MSCs in BMA, which restricted our flow cytometry and VEGF
quantification experiments only to cMSCs [40]. We also acknowledge the donor variations
that led to the lack of statistical significance in gene expression levels despite interesting
trends being observed.
This further emphasises the importance of studying primary human cells rather than
cell lines from mouse models, particularly from the individuals with co-morbidities [41,42]
in whom long-bone defects are particularly difficult to heal. Future work involving a higher
number of donors in each set of experiments and introducing imaging techniques will
provide further insight into the ability of B-HA scaffolds to encourage cellular activities,
including angiogenesis support and blood vessel ingrowth. This will help to shed light
on the potential of B-HA scaffolds in providing the ideal base for bone regeneration after
fracture. ELISA experiments following loading the B-HA with fresh BM aspirates will
provide further essential data for the use of these scaffolds in bone regeneration applications.
Furthermore, future in vivo studies in large-animal, long-bone defect models [30,43] would
be eventually required for the translation of these scaffolds to humans.
Overall, we successfully demonstrated that the B-HA scaffolds support the attach-
ment and survival of human cMSCs and BMSCs. We showed higher VEGF release from
supernatants collected with cMSC + E co-cultures, which when put together with comple-
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mentary data from others, is encouraging for future applications of biotemplated scaffolds
for large-bone defect repair.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/bioengineering9010001/s1, Figure S1: Microscopic images of both scaffolds under transmitted
light at 4X, Table S1: List for used genes, Table S2: VEGF release data from n = 3 BMSC donors.
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